Previous 10 | Next 10 |
Reneo Pharmaceuticals (RPHM) has joined the broad-market Russell 3000 Index, effective after the market close on June 28, 2021. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Ru...
SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, joined the broad-market Russell 3000 Index at...
Gainers: Trxade (MEDS) +100%, Reneo Pharmaceuticals (RPHM) +13%, ProPhase Labs (PRPH) +18%, Verona Pharma (VRNA) +13%, Myomo (MYO) +8%.Losers: Aethlon Medical (AEMD) -28%, Ocugen (OCGN) -23%, Ra Medical Systems (RMED) -16%, SCWo...
Gainers: Ra Medical Systems (RMED) +25%, Sundial Growers (SNDL) +24%, Kindred Biosciences (KIN) +14%, Lannett (LCI) +11%, IGM Biosciences IGMS +11%.Losers: PetMed Express (PETS) -25%, SELLAS Life Sciences (SLS) -15%, Replimune REPL ...
Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers
Reneo Pharmaceuticals (RPHM): Q1 GAAP EPS of -$3.48.The company had $91.2M in cash and cash equivalents as of March 31, 2021, exclusive of the net proceeds of ~$84.8M from the IPO.Press Release For further details see: Reneo Pharmaceuticals EPS misses by $2.99
SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quar...
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will present and par...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The three major U.S. stock averages rallied in the last two sessions of the week as inflation fears eased, but it wasn’t enough to off...
Growth beyond COVID for Quest DiagnosticsQuest Diagnostics (DGX) is poised for top-line growth even as COVID-19 testing wanes, according to UBS, which has upgraded shares from neutral to buy.Analyst Kevin Caliendo has also upped his price target to $158 from $135, implying upside of 19% from ...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...